Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer

MT Newswires Live

2024/11/22

Shanghai Henlius Biotech (HKG:2696) dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.

The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485254435"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485254435\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485254435?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485254435","market":"hk","top_or_hot":-1,"title":"Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer","media":"MT Newswires Live","content":"<html><body><p> Shanghai Henlius Biotech (HKG:2696) dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.</p><p>The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius Doses First Patient in Phase 3 Study of Combo Treatment for Gastric Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-22 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shanghai Henlius Biotech (HKG:2696) dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.</p><p>The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485254435","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485254435","pubTimestamp":1732278276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Henlius Biotech  dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy  versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖胃癌联合治疗3期研究首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech (HKG:2696) dosed the first patient in its international multi-center phase 3 clinical study of HLX22 in combination with Trastuzumab and chemotherapy as a first-line therapy for advanced or metastatic gastroesophageal junction and gastric cancer in mainland China.The study aims to compare the efficacy and safety of HLX22 combined with trastuzumab and chemotherapy (XELOX) versus trastuzumab and XELOX with or without pembrolizumab as a first-line treatment for advanced or metastatic gastroesophageal junction and gastric cancer, according to a Friday filing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}